Fexinidazole – NCT03025789
An open-label study assessing effectiveness,safety and compliance with fexinidazole in patients with human African trypanosomiasis due to T.b. Gambiense at any stage
Fexinidazole – NCT02184689
Efficacy and safety of fexinidazole in children at least 6 years old and weighing over 20 kg with human African trypanosomiasis (HAT) due to T.b. Gambiense: a prospective, multicentre, open study, plug-in to the Pivotal Study.
Fexinidazole – NCT02169557
Efficacy and safety of fexinidazole in patients with stage 1 or early stage 2 human African trypanosomiasis (HAT) due to T.b. Gambiense: a prospective, multicentre, open-label cohort study, plug-in to the Pivotal Study.
Fexinidazole – NCT01483170 [Terminated]
Multiple dose study to evaluate security, tolerance and pharmacokinetic of fexinidazole (drug candidate for human African trypanosomiasis) administered with a loading dose and with food.
Fexinidazole – NCT00982904 [Completed]
Human African trypanosomiasis: first-in-man clinical trial of a new medicinal product, fexinidazole.
Results in Clinical Pharmacokinetics (2014)
NECT-FIELD study – NCT00906880 [Completed]
Clinical study to assess the tolerability, feasibility and effectiveness of nifurtimox and eflornithine (NECT) for the treatment of T.b. Gambiense human African trypanosomiasis (HAT) in the meningo-encephalitic phase (NECT-FIELD).
Results in PLOS NTDs (2012)
Eflornithine-nifurtimox combination – NCT00146627 [Completed]
Efficacy – Clinical study comparing the nifurtimox-eflornithine combination with the standard eflornithine regimen for the treatment of T.b. Gambiense human African trypanosomiasis in the meningoencephalitic phase.
Results in The Lancet (2009)